[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospitals and Clinics of Minnesota\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,79,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":46,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100315102","international-ppbdicer1-registry-100315102",false,"NCT03382158","International PPB\u002FDICER1 Registry","International Pleuropulmonary Blastoma\u002FDICER1 Registry (for PPB, DICER1 and Associated Conditions)","Inclusion Criteria:\n\n1. Known or suspected PPB or related thoracic tumor\n2. Known or suspected sex-cord stromal tumor including Sertoli-Leydig cell tumor and gynandroblastoma (males or females)\n3. Other known or suspected DICER1-related condition including ovarian sarcoma, cystic nephroma, renal sarcoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma and others\n4. Individuals with known or suspected DICER1 pathogenic variation regardless of whether they have an established DICER1-associated condition\n5. Informed consent by patient\u002F or parent\u002Fguardian (also, where appropriate: assent and HIPAA consent)\n\nExclusion criteria:\n\nAbsence of appropriate consent for Registry participation",true,"ALL","0 Minutes","100 Years",{"count":21,"type":22},3400,"ESTIMATED","10 Years","OBSERVATIONAL","Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Pleuropulmonary Blastoma","Sertoli-Leydig Cell Tumor","DICER1 Syndrome","Cystic Nephroma","Wilms Tumor","Pineoblastoma","Renal Sarcoma","Nodular Hyperplasia of Thyroid","Nasal Chondromesenchymal Hamartoma","Ciliary Body Medulloepithelioma","Neuroblastoma","Pituitary Cancer","Embryonal Rhabdomyosarcoma","Ovarian Sarcoma","Gynandroblastoma","Thyroid Carcinoma","Embryonal Rhabdomyosarcoma of Vagina (Diagnosis)","Embryonal Rhabdomyosarcoma of Uterus (Diagnosis)","Embryonal Rhabdomyosarcoma of Cervix",[47,48,49,50,28,30,51,52,53,31,32,33,54,34,55,42,35,56,36,57,37,38,39,58,40,41,59,60,61,62,63,64,65],"pleuropulmonary blastoma","PPB","DICER1","SLCT","CN","DICER1 mutation","DICER1 syndrome","ASK","Thyroid Nodules","NCMH","CBME","ERMS","Peritoneal PPB","pPPB","multinodular goiter","PPB Type I","PPB Type II","PPB Type III","PPB Type Ir","RECRUITING","2025-01-28",{"date":69,"type":70},"2025-01-30","ACTUAL",{"date":72,"type":70},"2016-12-06",{"date":74,"type":22},"2035-12-06",{"name":76,"class":77},"Children's Hospitals and Clinics of Minnesota","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":86,"maxAge":19,"enrollmentInfo":87,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":78},"100206946","international-ovarian--testicular-stromal-tumor-registry-100206946","NCT01970696","International Ovarian & Testicular Stromal Tumor Registry","OTST","Inclusion Criteria:\n\n* Previous or current diagnosis of an ovarian sex cord stromal including but not limited to: Sertoli-Leydig cell tumor, gynandroblastoma (now enrolling these patients on PPB\u002FDICER1 Registry), juvenile granulosa cell tumor, Sertoli cell tumor, sex cord-stromal tumor with annular tubules or undifferentiated stromal tumor\n* Previous or current diagnosis of a testicular stromal tumor including but not limited to: juvenile granulosa cell tumor, Sertoli cell tumor, Leydig cell tumor or undifferentiated stromal tumor\n\nExclusion Criteria:\n\n* Unable to provide informed consent\u002Fassent\n* Adult Granulosa cell tumor (unless otherwise specified by Medical Director)","0 Years",{"count":88,"type":22},300,"Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a lung cancer of early childhood called pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1 mutations are seen in the majority of children with PPB. Research shows DICER1 mutations are also seen in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly curable when found in early stage; however, later forms of the disease are aggressive and often fatal. The International Ovarian Stromal Tumor Registry collects clinical and biologic data to understand why these tumors occur and how to treat them. Current work involves the study of the role of DICER1 and miRNA expression in ovarian stromal tumors. Understanding the clinical history, predisposing factors and DICER1 and miRNA expression in these ovarian tumors of childhood will lead to targeted screening and risk stratification for evidence-based treatment and biologically rational therapies. These efforts will improve the lives of children by increasing survival and reducing late effects.\n\nThe specific goals of the International Ovarian and Testicular Stromal Tumor Registry are:\n\n1. to understand risk factors by studying age, pathologic subtype, histopathologic features, tumor invasiveness, degree of differentiation, presence of metastasis\n2. to collect information on personal and family history in order to refine the clinical characteristics of patients and families with and without germline DICER1 mutations and other genetic predisposing factors\n3. to determine whether there is a pattern of gene expression or DNA alterations that correlate with predisposition to ovarian tumors, biologic behavior and clinical outcome\n4. to determine optimal screening regimens\n5. to use clinical data obtained through the Registry to refine treatment algorithms\n6. to establish a collection of annotated biology specimens (tumor tissue and germline DNA) for future research",[91,92,93],"Ovarian Sex-cord Stromal Tumor","Testicular Stromal Tumors","Ovarian Small Cell Carcinoma",[95,96,97,98,99,100,101],"ovarian","testicular","stromal","sertoli","leydig","juvenile granulosa cell tumor","gynandroblastoma","2024-08-20",{"date":104,"type":70},"2024-08-22",{"date":106,"type":70},"2011-12-08",{"date":108,"type":22},"2030-12",{"name":76,"class":77},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":118,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":78},"100498548","fetoscopic-endoluminal-tracheal-occlusion-100498548","NCT05771688","Fetoscopic Endoluminal Tracheal Occlusion","Fetoscopic Endoluminal Tracheal Occlusion for Severe Left-sided Congenital Diaphragmatic Hernia","FETO","Inclusion Criteria:\n\n1. A subject is defined as a female (18 years or older) who is pregnant.\n2. The pregnancy must be a singleton pregnancy.\n3. The CDH must be left-sided.\n4. The CDH must be severe (Observed to Expected Lung to Head Ratio - O\u002FE LHR - \\\u003C 25% from U\u002FS measurements).\n5. No associated lethal anomalies (other than the CDH), no pathogenic variants on microarray, and no pathologic findings on karyotype.\n6. Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects.\n7. Gestational age at time of balloon placement between and including 27 weeks 0 days and 29 weeks 6 days.\n8. Cervix length longer than 20 mm at pre-balloon placement evaluation.\n9. Acceptance of responsibility to stay locally (within 15 minutes) of MWFCC and Children's Minnesota - Minneapolis.\n10. Written consent must be obtained.\n11. Must meet psychosocial criteria including appropriate family\u002Ffriend support during stay with balloon in place (cannot stay without additional helper), no current illicit drug use, no over-the-counter drug abuse, and no ineffectively treated DSM-IV diagnoses.\n\nExclusion Criteria:\n\n1. Twin or higher order gestation\n2. Not able to consent\n3. Right-sided or bilateral CDH\n4. Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome\n5. Maternal isoimmunization or neonatal alloimmune thrombocytopenia\n6. Balloon not able to be placed prior to 30 weeks gestation\n7. CDH O\u002FE LHR 25% or greater\n8. Maternal factors precluding safe fetal surgery (maternal cardiac findings not safe for anesthesia, maternal morbid obesity precluding safe usage of the equipment required for entry into the uterus, spontaneous preterm delivery prior to 36 weeks)\n9. Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risks of fetal transmission during procedures\n10. Short cervix (20 mm or less)\n11. History of incompetent cervix or uterine anomaly predisposing to preterm labor\n12. Significant placental abnormalities (abruption, chorioangioma, accrete) known at the time of enrollment and\u002For surgery\n13. History of natural rubber latex allergy\n14. No safe or feasible fetoscopic approach to balloon placement\n15. Inability to relocate to within 15 minutes of MWFCC\u002FChildren's Minnesota","FEMALE","18 Years",{"count":121,"type":22},10,"INTERVENTIONAL",[124],"NA","This is a single site pilot trial to study the feasibility of Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in the most severe group of fetuses with congenital diaphragmatic hernia (CDH) at Midwest Fetal Care Center, a collaboration between Allina Health and Children's Minnesota. This procedure aims to increase fetal lung volume before birth and improve survival after birth. This study will enroll 10 pregnant people and their baby who meet study criteria.",[127],"Hernia, DIaphragmatic, Congenital","2024-02-22",{"date":130,"type":70},"2024-02-23",{"date":128,"type":70},{"date":133,"type":22},"2028-09",{"name":76,"class":77},""]